Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/2237
Title: Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells
Authors: Hassan, Marwa Al
Fakhoury, Isabelle
Masri, Zeinab El
Ghazale, Noura A.
Dennaoui, Rayane
Atat, Oula El
Kanaan, Amjad 
Sibai, Mirvat El
Affiliations: Faculty of Medicine 
Issue Date: 2018
Part of: Journal of analytical cellular pathology
Volume: 2018
Abstract: 
Glioblastoma multiforme (GBM) is one of the most common and deadliest cancers of the central nervous system (CNS). GBMs high ability to infiltrate healthy brain tissues makes it difficult to remove surgically and account for its fatal outcomes. To improve the chances of survival, it is critical to screen for GBM-targeted anticancer agents with anti-invasive and antimigratory potential. Metformin, a commonly used drug for the treatment of diabetes, has recently emerged as a promising anticancer molecule. This prompted us, to investigate the anticancer potential of metformin against GBMs, specifically its effects on cell motility and invasion. The results show a significant decrease in the survival of SF268 cancer cells in response to treatment with metformin. Furthermore, metformins efficiency in inhibiting 2D cell motility and cell invasion in addition to increasing cellular adhesion was also demonstrated in SF268 and U87 cells. Finally, AKT inactivation by downregulation of the phosphorylation level upon metformin treatment was also evidenced. In conclusion, this study provides insights into the anti-invasive antimetastatic potential of metformin as well as its underlying mechanism of action.
URI: https://scholarhub.balamand.edu.lb/handle/uob/2237
DOI: 10.1155/2018/5917470
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record

SCOPUSTM   
Citations

10
checked on May 1, 2021

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.